<DOC>
	<DOCNO>NCT02886195</DOCNO>
	<brief_summary>The aim study compare efficacy EGFR-TKIs ( Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitors ) treatment plus concurrent chemotherapy versus sequential treatment EGFR-TKIs chemotherapy patient EGFR ( Epidermal Growth Factor Receptor ) -mutant non-small-cell lung cancer ( NSCLC ) .</brief_summary>
	<brief_title>EGFR-TKIs Combine Chemotherapy First-line Therapy Patients With Advanced EGFR Mutation-positive NSCLC</brief_title>
	<detailed_description>This open-label , randomize , parallel-group control clinical trial , study subject recruit study NSCLC patient mutant EGFR gene ( 19del L858R ) . Subjects concurrent therapy group give EGFR-TKIs treatment plus concurrent chemotherapy . Patients sequential treatment group assign sequential EGFR-TKIs follow chemotherapy group , receive TKIs monotherapy chemotherapy alone disease progression ; sequential chemotherapy follow EGFR-TKIs treatment , give first-line chemotherapy 4 6 cycle , follow maintenance therapy EGFR-TKIs . The endpoint study include clinical efficacy safety .</detailed_description>
	<mesh_term>Cisplatin</mesh_term>
	<mesh_term>Erlotinib Hydrochloride</mesh_term>
	<mesh_term>Pemetrexed</mesh_term>
	<criteria>Stage â…£ EGFR mutationpositive NSCLC Initial therapy ECOG performance status 01 EGFR mutationnegative Previous systemic antitumour treatment</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>July 2016</verification_date>
</DOC>